ProQR Posts €12.4M Q3 Loss, Cash of €103M Funds Runway Into Mid-2028
PRQR is trading near its 52-week low of $1.2 (5.0% above the low).
Summary
ProQR reported a Q3 2026 net loss of €12.4 million, or €0.09 per diluted share, versus €11.0 million a year earlier, as R&D spending rose to €14.3 million from €11.1 million, while Q3 revenue rose and beat analyst estimates. Cash and equivalents stood at €103.0 million at September 30, up from €92.4 million at year-end 2025 after a €48.9 million share issuance, and management says that funds operations into mid-2028. Net cash used in operations was €13.6 million for the quarter. The operating update is the bigger part of the story: the first two cohorts of the AX-0811 Phase 1 study are fully enrolled, with initial target engagement data expected in early January 2027, and the full AX-0810 Phase 1 dataset including Cohort 3 and 12-week follow-up will be presented in December 2026. Beyond that, ProQR points to a biliary atresia investigator-initiated trial in China, AX-0422 initial patient data in MPS I Hurler syndrome, and AX-2911 moving into the clinic for MASH, all targeted for the first half of 2027. With the stock near its 52-week low of $1.20, the December and January readouts are the events that will decide direction; the quarterly numbers themselves are largely a cash-runway confirmation.
At the time of this announcement, PRQR was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.8M. The 52-week trading range was $1.20 to $2.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.